There is an imminent need to increase awareness among general physicians about the long term risk of an episode of AKI and the improved outcomes with early referral and follow up by a nephrologist. This review highlights the importance of recognising the renal and non-renal consequences following an episode of AKI, and the available biomarkers for this condition.
SUMMARY AT A GLANCE
There is an imminent need to increase awareness among general physicians about the long term risk of an episode of AKI and the improved outcomes with early referral and follow up by a nephrologist. This review highlights the importance of recognising the renal and non-renal consequences following an episode of AKI, and the available biomarkers for this condition.
ABSTRACT:
With increasing longevity and the presence of multiple comorbidities, a significant proportion of hospitalized patients, and an even larger population in the community, is at increased risk of developing an episode of acute kidney injury (AKI). Because of improvements in short-term outcomes following an episode of AKI, survivors of an episode of AKI are now predisposed to develop its long-term sequel. The identification of risk for progression to chronic kidney disease (CKD) is complicated by the absence of good biomarkers that identify this risk and the variability of risk associated with clinical factors including, but not limited to, the number of AKI episodes, severity, duration of previous AKI and pre-existing CKD that has made the prediction for long-term outcomes in survivors of AKI more difficult. Being a significant contributor to the growing incidence of CKD, there is a need to implement measures to prevent AKI in both the community and hospital settings, target interventions to treat AKI that are also associated with better long-term outcomes, accurately identify patients at risk of adverse consequences following an episode of AKI and institute therapeutic strategies to improve these long-term outcomes. We discuss the lasting renal and non-renal consequences following an episode of AKI, available biomarkers and non-invasive testing to identify ongoing intra-renal pathology and review the currently available and future treatment strategies to help reduce these adverse long-term outcomes.
The increasing prevalence of risk factors of acute kidney injury (AKI) in the community, frequent interventions in the high-risk groups and standardization in defining AKI have all contributed to a measured increase in the incidence of AKI, both in the community and in-hospital settings, over the last decade. 1 A clinical state that was once thought to be completely reversible is now well established, both in animal models and human survivors, as a predictor for the future development of chronic kidney disease (CKD), hastening the progression of pre-existing CKD and carrying an increased long-term risk of end-stage renal failure (ESRD) and early mortality. 2 In addition to the increasing incidence, improvement in the survival of patients after an episode of AKI, despite their increased comorbidities, has also contributed to the growing incidence of CKD and ESRD globally. 3 Two observational studies in the last decade using National Health and Nutrition Examination Surveys and Nationwide Inpatient Sample data by Hsu et al. and Waikar et al., respectively, found that the increase in the incidence of ESRD was higher than the increase in the prevalence of CKD. Patients who survived an episode of AKI attributed as high as 25% to the increase in incidence of ESRD, making AKI one of the major causes of ESRD in the USA. 4, 5 The importance of prevention of AKI was recognized by the International Society of Nephrology (ISN), which initiated the 0 by 25 initiative, aimed to reduce the global mortality of AKI. 6 The ISN also hosted a CKD summit in 2016 to identify and tackle major risk factors for CKD and emphasized the need to reduce AKI, identifying it as a modifiable risk factor for CKD. 7 As traditional risk factors for CKD and ESRD are well understood and better managed, the extended ramifications of an episode of AKI and the long-term management of AKI survivors are areas likely to receive more attention, with a proportionate increase in research and understanding over the next decade. 7 In this review, we focus on current evidence for long-term renal and non-renal systemic effects following an episode of AKI and discuss the general approach to managing patients who survive an episode of AKI.
NATURAL COURSE OF AKI
Apart from its short-term impact on hospitalizations and mortality, concerns regarding the long-term impact of an episode of AKI have been an area that has received attention in the last few decades. Goldstein et al. summarized this and identified three patterns based on the severity and duration of the insult. Following an acute injury, renal function would return close to its baseline value, remain stable for a variable period of time and then progress to CKD (subclinical CKD), or the recovery in renal function may be only partial and result in 'established CKD'. In the third situation, if the injury was severe and/or of considerable duration, it would necessitate a permanent need for renal replacement therapy (RRT) from the outset. 8 Community-acquired episodes of AKI outnumber the incidence of hospital-acquired AKI by 2-3 times and are often under-reported, especially from the developing world. 6, 13 An approximation from the developed world on the incidence and outcomes of AKI estimate 2147 AKI episodes per million population annually, of which 10-15% die during the acute insult, 3-15% patients develop ESRD and 20-50% progress to CKD. 8 In addition, patients with baseline normal renal function who experience an episode of AKI and later progress to CKD continue to be at an increased risk of mortality long after the acute phase, which is estimated to be 3-fold compared with patients without an episode of AKI 11 (Fig 1) .
Other factors that influence the natural course of AKI, in addition to baseline residual renal reserve and proteinuria, are: severity of AKI, duration of an AKI episode, recurrent episodes of AKI and patient comorbidities (disease modifiers). Morgera et al., in their cohort of dialysis-requiring AKI patients, observed 10% of patients progressing to ESRD at the end of 2.5 years of follow up.
14 Similarly, Lo et al.,
over an 8-year period, observed that patients with AKI who required dialysis but were dialysis independent at 30 days after hospital discharge had a 28-fold higher risk of having CKD stage 4, when compared with patients who experienced non-dialysis-requiring AKI. 15 In a risk model used to predict progression of AKI to CKD amongst patients hospitalized in the Veterans Affairs (VA) Healthcare System with 17 In addition, increasing duration of an AKI episode has been found to be positively correlated with long-term mortality risk. 18 With regard to the aetiology of AKI and its impact on patient and renal outcomes, Choi et al. analysed their prospective cohort of 203 adults who experienced dialysisrequiring AKI. Sepsis (42%) followed by postoperative AKI (30%) and cardio-renal syndrome (12%) accounted for the majority of anuric AKI patients in their cohort. In addition, in the multivariate model, they observed a 69% increased risk of mortality at 90 days following an AKI episode due to sepsis (adjusted HR 1.69; 95% CI = 1.04-2.76; P value 0.036). 19 Among the paediatric population, Duzova et al. identified hypoxia/ischaemic insult and sepsis as the leading causes for AKI across all age groups. AKI was secondary to pre-renal, intrinsic and obstructive in 40, 58.4 and 1.6% in children beyond neonatal period, respectively. Intrinsic AKI was a major independent risk factor for mortality in this population (RR 4.91; 95% CI = 2.04-11.78; P value <0.001). 20 
ACUTE KIDNEY DISEASE
To further bridge the knowledge gap between AKI and CKD, the Acute Disease Quality Initiative (ADQI) 16 Workgroup published a consensus report where they further defined the term AKD and emphasized the importance of the post-AKI period, especially in patients with ongoing renal patho-physiological processes 21 (see below). A suggestion was made that the appropriate interventions initiated during this critical time period may alter the course of AKI, resulting in improvements in long-term outcomes. The Workgroup defined AKD as a condition in which 'AKI stage 1 or greater, as defined by KDIGO, is present ≥7 days after an AKI initiating event'. The group further theorized the view of AKD as a 'post-AKI phase' and not a 'pre-CKD stage', and outcomes of AKD include recovery, recurrence of AKI, progression of AKD to CKD and/or death. 21 Corresponding to the KDIGO AKI staging, the group proposed staging for AKD based on the patient's renal status after 7 days and up to 90 days from an injury. The group added a stage 0 (subacute) AKD apart from the AKD stages 1, 2 and 3 and ongoing RRT. Stage 0 AKD was further subtyped to A, B and C to highlight the potential long-term risk for renal and non-renal outcomes and the need for long-term follow up even in patients in whom renal functions returned to pre-AKI levels. Stage 0C includes patients for whom serum creatinine levels are higher than baseline but within 1.5 times the baseline levels. Stage 0B includes patients whose serum creatinine has returned to baseline levels but who still have evidence of ongoing kidney damage, injury or loss of renal reserve, identified either by new-onset proteinuria or worsening of baseline proteinuria, new-onset hypertension or worsening hypertension or the presence of other biomarkers or imaging studies reflecting ongoing injury or persistent damage. Stage 0A includes those patients who have had an episode of AKI but retain a risk of long-term events without structural or damage markers for AKD. 21 
PRE-EXISTING CKD AND AKI
Patients with CKD are at an increased risk for AKI, and following AKI, the decline in GFR follows a nonlinear pattern. They often require in-hospital care to manage their AKI episode, and the outcomes are generally poor with a longer duration of RRT, compared with patients without pre-existing CKD. 22 The interplay between a pre-existing CKD and AKI , the HR for AKI increased from 1.03-2.63 to 5.34-9.38 across urinary albumin: creatinine ratios of less than 10, 10-29, 30-299 and >300 mg/g, respectively. 25 Reduced renal reserve, failure of autoregulation, abnormal vasodilatation, endothelial dysfunction and side effects of medication may be some of the mechanisms of an increased risk of AKI in patients with pre-existing CKD. Sawhney et al. reviewed data from observational studies on hospital-acquired AKI and concluded that the presence of CKD prior to the episode of AKI was associated with the doubling of mortality and a 4-to 5-fold increase in poor renal outcomes with progression to ESRD compared with patients with AKI and without pre-existing CKD. 26 
LONG-TERM SYSTEMIC CONSEQUENCES OF AKI
Patients surviving an episode of AKI are at an increased risk of death. This was observed in the extended follow-up cohort of 'day 90 AKI survivors' from the original RENAL study group over 4 years, which reported a mortality rate of 32% and pointed to the residual systemic effects of an episode of AKI. 27 Regardless of an underlying cardiovascular disease, patients who survive an episode of AKI are at an increased risk of major cardiovascular events, 23, 28 which is in addition to the cardiovascular risk contributed by the development of CKD after an AKI insult. Odutayo et al. conducted a meta-analysis of studies looking into the long-term risk of cardiovascular mortality and cardiovascular disease in adults surviving an episode of AKI. After a median follow up of 2.6 years (interquartile interval 1.2-3.4), authors observed that AKI was associated with an 86% increased risk of cardiovascular mortality and a 38% increased risk of major cardiovascular events. AKI was also associated with a 58% increased risk of Congestive Heart Failure (CHF) and a 40% increased risk of acute myocardial infarction. 29 In patients who developed AKI at the time of percutaneous coronary intervention and were followed up later for occurrence of cardiovascular events at 1 year after AKI, 15.4% of survivors of AKI and 7.0% of survivors without AKI had suffered a myocardial infarction (MI), and the increased risk of MI persisted over time (relative risk 1.6, 1.85 and 1.75 at 0.5, 1 and 5 years, respectively), pointing to the possible long-term distant site adverse outcomes associated with AKI. 30, 31 In an analysis of the Veteran Affairs patient database by Chawla et al., 81% of patients were free from major acute cardiovascular outcomes at 1 year in the MI only group compared with 75% in the MI + AKI group. AKI was associated with increased rates of subsequent hospitalization for stroke, heart failure or MI than the rates associated with previous MI. 32 They postulated that acute cardio-renal injury may induce a vicious cycle that persists long after the acute event, plausibly due to 'organ crosstalk'. Kelly et al. demonstrated, in preclinical models, that AKI can result in distant organ effects that include cardiac cell apoptosis and cardiac leukocyte infiltration. 33 Ratliff et al., in their review, concluded that 'AKI is a paradigm of a localized damage triggering systemic inflammatory disease', and when inflammatory response is severe or prolonged, it may involve other organs such as the heart, lungs and liver. 34, 35 Following ischaemia-reperfusion injury, animal studies implicate increased angiotensin-converting enzyme expression and alteration in the affinity of the calcium receptor in the heart for inotropic agents as postulated pathways for the increased cardiovascular risk. 36, 37 Other systemic and non-cardiac effects of AKI have also been documented. In a large matched cohort of more than 4000 patients, an observation was made that the incidence and severity of stroke was higher (HR = 1.25; P = 0.037) in the AKI group compared with the non-AKI group. 38 In their meta-analysis, Odutayo et al. observed that AKI was associated with a 15% increased risk of stroke over a median follow up of 2.7 years when compared with patients without an AKI. 29 Survivors of an AKI episode are 20% more likely to be hypertensive on follow up, and animal experiments by Spurgeon-Pechman et al. established that the recovery from AKI associated with ischaemia-reperfusion injury is often incomplete, with long-term effects on sodium haemostasis, which predisposes to the future development of hypertension. 39, 40 This was also recognized by Askenazi et al. in their 3-to 5-year longitudinal follow up of paediatric AKI survivors, who developed hypertension as a sequel, further endorsing the long-term systemic consequences of an AKI episode. 41 One of the best pieces of evidence for long-term consequences of an AKI was illustrated by Tangren et al., who demonstrated adverse future pregnancy outcomes in women with a history of clinically recovered AKI (r-AKI). Women with r-AKI had an increased risk of preeclampsia (OR = 4.7; 95% CI = 2.1-10.1) and adverse foetal outcomes (OR = 2.1; 95% CI = 1.2-3.7) during subsequent pregnancies, compared with women with no previous AKI episodes. 42 Liangos et al., in their US national survey looking at outcomes of AKI in hospitalized patients, observed that patients recovering from an episode of AKI were twice as likely to require transfer from hospital to a long-term care facility compared with those without an AKI. 43 
PATHOPHYSIOLOGY OF AKI TO CKD TRANSITION
Better understanding of the pathophysiology in the progression of AKI to CKD would help to identify potential therapeutic targets and formulate management strategies. The 13th Acute Dialysis Quality Initiative meeting in 2014, entitled 'Therapeutic Targets of Human Acute Kidney Injury: Harmonizing Human and Experimental Animal Acute Kidney Injury', was able to improve our understanding of the transition and progression from AKI to CKD. 44 However, in recent times, more evidence has pointed towards AKI being directly related to the subsequent development of CKD, in that the risk factors which predispose to an AKI event (such as metabolic syndrome, obesity, hypertension, diabetes and cardiovascular diseases) often continue to persist after recovery from AKI and may predispose to the development of CKD in the future, without any causal link with the prior AKI episode. 45 However, the occurrence of CKD in children who had recovered from AKI and had no other coexisting conditions that predispose to CKD supports the former. 46 Preclinical studies suggest that there is a threshold for the development and progression to CKD compared with normal kidney repair and regeneration. 8 Progression to CKD occurs due to a loss in renal reserve and from incomplete or imperfect repair following the acute insult. Considering the clinical course of AKI in three phases, the consequences of the 'Developmental phase', which represents the immediate period following an insult, mainly depend on the underlying renal reserve that often compensates for the GFR and limits the clinical (urine output) or biochemical (often serum creatinine) changes seen after the acute insult. In patients with advancing age, associated comorbidities and those who have had previous/recurrent AKI episodes, this phase may not be adequately represented due to low underlying renal reserve, and patients often proceed to the 'Extension phase' of AKI. In this phase, both the injury and repair mechanisms are in play, and evidence of damage and functional changes becomes apparent. When an injury is severe, that is, in those needing dialysis, patients may fail to achieve adequate recovery, resulting in progression to CKD after the initial episode. The 'Resolution phase' represents the net result of the injury and repair mechanisms. 44 Repair can be both adaptive and maladaptive, and the final outcome of recovery or progression is dependent on balance of each of these processes, independent of the initial aetiology of AKI. Irrespective of the primary compartment that is involved in AKI (glomerular, vascular, tubular or interstitium), a final common pathway of maladaptive repair ensures progression of AKI to CKD. An interplay of renal functional mass, glomerular hypertension, inflammatory cell infiltration and cytokine release, vascular rarefaction and tissue hypoxia, cell cycle arrest and failure of re-differentiation results in interstitial fibrosis and scarring, which are features of maladaptive repair that is further influenced by factors such as recurrent insults, severity and duration of AKI. 47 Injury to proximal tubules alone is sufficient to initiate the downstream pathways of interstitial fibrosis and progression of AKI. The renal tubules and peritubular blood vessels are in a delicate harmony, held together by pericytes and interstitial microenvironment. Following injury to renal tubules, repair often occurs through the de-differentiation of surviving resident renal tubular cells, which transiently express putative stem cell markers. 48 Recent evidence from experiments by Kramann et al. strongly refute the role of resident tubular stem cells or pluripotent stems cells originating outside kidney in tubular regeneration. 48 The de-differentiated tubular cells proliferate and undergo redifferentiation to replace the damaged tubular epithelium.
In addition, a disturbance in the paracrine signals between the vascular, tubular and interstitial compartments also prevent adaptive repair. For example, a reduction in the capillary density secondary to an AKI insult exacerbates tissue hypoxia (as evidenced by increased HIF expression), which then sets off a chain of events, forming a vicious cycle. 49 Sustained expression of kidney injury molecule-1 (KIM-1), 50 arrest of cell cycle at G2/M phase, failure of re-differentiation, increased production of TGF-β, 51 epigenetic alterations, apoptosis and decreased synthesis of VEGF 52 are some of the events identified at the level of injury to proximal tubules. Hypoxia also results in inflammatory cell infiltration in the interstitium, which further secretes pro-fibrotic cytokines. 53 This, together with the TGF-β secreted by the arrested tubular cells, transforms the resident fibroblasts and pericytes in the interstitium to myofibroblasts, which then initiates the process of interstitial fibrosis. The dysangiogenic VEGF signals form the tubular cells, and the loss of intact pericytes further amplifies the loss of endothelial integrity, setting off a vicious cycle of vascular rarefaction, interstitial fibrosis and maladaptive repair. The reduced renal mass then has a haemodynamic influence on the surviving glomeruli, resulting in glomerular hypertension, misdirected filtration, loss of tubule-glomerular feedback and eventually glomerulosclerosis 44, 47, 54, 55 (Fig 2) .
ROLE OF BIOMARKERS
The correlation between AKI episodes and the subsequent development of CKD in patients who regain serum creatinine levels highlights the limitation of serum creatinine as a functional biomarker as it may not truly reflect complete recovery from AKI. Similarly, traditional biomarkers for CKD, including serum creatinine, cystatin C and proteinuria, are often used for eGFR assessment and risk prediction of CKD progression. Hus et al., in their study, demonstrated the ineffectiveness of serum creatinine to differentiate between natural progression of CKD and 'acute on chronic' disease. 24 Patients with maladaptive repair may continue to have residual structural damage that is not picked up by traditional biomarkers, which therefore cannot identify patients who are likely to progress to CKD in the future. Therefore, patients with AKI who have complete recovery, as assessed by the traditional biomarkers, would need to be followed up over extended periods to detect progression to CKD, and our inability to identify these patients would translate into a missed opportunity in effectively managing these patients to either halt or retard progression to CKD. Biomarkers used in AKI research typically reflect a specific component of pathophysiology, including tubular injury, cell cycle arrest, systemic inflammatory pathways and glomerular filtration. 56 They have historically been used to predict clinical outcomes, facilitate appropriate referrals, inform clinical decision making and assess response to therapy. These novel biomarkers, either individually or when used in combination, have shown good correlation with short-term outcomes, such as in-hospital mortality, need for RRT and length of hospital stay. 56 One of the well-conducted studies to assess any link between biomarkers of AKI and long-term mortality was conducted by Coca et al. 57 This was a prospective long-term follow-up study from six centres in United States and Canada involving patients who underwent cardiac surgery and enrolled in the Translational Research in Biomarker Endpoints in AKI (TRIBE-AKI) cohort. Urinary biomarkers were measured on postoperative days 1-3, and patients had a median follow up of 3.0 years (interquartile range 2.2-3.6 years). Among patients with clinical AKI, the highest tertiles of peak urinary neutrophil gelatinaseassociated lipocalin (NGAL), interleukin-18 (IL-18), KIM-1, liver fatty acid binding protein (L-FABP) and albumin were independently associated with a 2.0-to 3.2-fold increased risk for long-term mortality compared with the lowest tertiles. More importantly, authors observed that, in patients with subclinical AKI, the highest tertiles of peak IL-18 and KIM-1 also independently predicted long-term mortality with adjusted HR (95% CI) of 1.2 (1.0-1.5) and 1.8 (1.4-2.3), respectively. IL-18 and KIM-1 provided additional prognostic information for 3-year mortality risk in patients with and without clinical AKI, when measured in the immediate postoperative period 57 (Table 1) .
Koyner et al. prospectively evaluated urinary tissue inhibitor metalloproteinase (TIMP-2) and IGF-binding protein-7 (IGFBP7), biomarkers of cell cycle arrest and their association, for a composite end-point of all-cause mortality or the need for RRT at the end of 9 months in critically ill adults admitted to ICU. These biomarkers were measured early in the critical illness, and the researchers showed that the link between these biomarkers and the composite end-point was specific to subjects who develop AKI within 72 h of measurement. An elevated product of TIMP-2 and IGFBP7, even in patients with mild AKI, was associated with poor prognosis, and levels of >2 were associated with HR of 2.16 (95% CI = 1.32-3.53; P = 0.002) when compared with levels of ≤0.3. However, the correlation was specific for clinical AKI and did not show any association with cases of subclinical AKI 58 (Table 1) . In patients with cardio-renal syndrome, tubular injury biomarkers, including urinary NGAL, KIM-1 and N-acetyl-β-D-glucosaminidase (NAG), have been consistently associated with long-term mortality and adverse outcomes, such as recurrent heart failure and hospitalizations 59, 60 (Table 1 ). In addition, in renal transplant recipients, elevated donor and/or recipient urinary tubular injury biomarkers have been shown to be adversely associated with long-term graft failure and mortality [61] [62] [63] (Table 1) .
One of the major limitations for biomarker research in AKI has been the inability of biomarkers to predict longterm organ-specific outcomes such as CKD and cardiovascular disease after an AKI episode. Other potential areas of research include identification of biomarkers that can specifically describe the underlying pathology of ongoing injury or repair of renal parenchyma at various time points after 'recovery' as that would add value to the long-term monitoring of survivors of AKI. Biomarkers that help distinguish AKI episodes from chronic kidney dysfunction could be valuable in determining where 'AKI finishes and CKD starts', which may have significant therapeutic implications. 64 Use of biomarkers to identify subclinical AKI (normal serum creatinine with elevated biomarkers of tubular injury) and biomarkers to identify ongoing or repeated subclinical injury following return of renal function to pre-AKI levels are other potential areas of research that could have implications in assessing the contribution of subclinical events to the future development of CKD. In addition, the long-term predictive ability of biomarkers when compared with traditional clinical scores has only been modest. 56 This could partly be because AKI occurring in different clinical situations from varied aetiologies and the multiple episodes of clinical/subclinical AKI occurring in the same individual may affect the ability of these biomarkers in predicting longterm clinical trajectories. Some of these concerns have been addressed in recent years by investigators. 24 One such biomarker is urinary KIM-1, which has shown to be a predictor of both AKI and the progression of CKD in patients with type 1 diabetes. 65 Biomarkers such as urinary connective tissue growth factor, matrix metalloproteinases, TIMP, type 4 collagen and the DNA methylation profile of genes implicated in inflammation and fibrosis such as TGF-β may be clinically helpful in the future to indicate intra-renal fibrosis and ongoing repair process as markers of underlying CKD. In addition, furosemide stress testing to predict recovery from AKI and intravenous creatinine have been used in clinical settings to detect subclinical reduction in renal functioning mass and tubular functional reserve. 66, 67 The ASsessment, Serial Evaluation, and Subsequent Sequelae of AKI (ASSESS-AKI) study is an ongoing prospective study looking into biomarkers of AKI that can provide additional prognostic information on long-term outcomes such as cardiovascular events and CKD, beyond those provided by the AKI event itself. 68 
LONG-TERM MANAGEMENT IN AKI SURVIVORS: STRATEGIES TO PREVENT PROGRESSION TO CKD AFTER AKI
Identifying patients at risk of poor long-term outcomes and defining timelines for non-recovery from an AKI episode
Studies looking into the long-term outcomes have been unanimous in observing the increased mortality risk in survivors of AKI compared with those without clinical or subclinical AKI. This increased risk continues to persist beyond the acute period and could partially be attributed to the subsequent development of CKD and ESRD. 8, 9, 11, 69 Progression to CKD as a result of maladaptive repair could be predicted, although with some uncertainty, using both clinical parameters and traditional biomarkers. Bucaloiu et al., in their retrospective study, which included hospitalized patients who survived an episode of AKI and did not have apparent preexisting renal disease (often considered a low-risk group), identified baseline parameters that were more commonly associated with poor long-term outcomes, especially the development of de novo CKD. Older patients, patients admitted with congestive heart failure, higher Charlson comorbidity score, history of hypertension, longer index hospitalization and increasing severity of AKI at the time of index admission had an increased prediction to develop subsequent CKD, while patients with higher baseline serum albumin (a marker of nutrition and inflammation) and higher eGFR were associated with a lower risk of de novo CKD during median longitudinal follow up of 3.3 years (IQR = 2.4, 4.3). The majority of patients had only a modest rise in serum creatinine with a rapid recovery in renal function but were associated with a 90% (HR = 1.91; 95% CI = 1.75-2.09; P < 0.0001) increased risk of developing CKD during the follow up. 11 Goldstein et al., in their commentary on transition of care after AKI, had additionally summarized the presence of pre-existing diabetes mellitus as a predictor for development of CKD. 8 As highlighted previously, patients with pre-existing CKD (as defined by proteinuria or reduced eGFR) are not only at an increased risk of new AKI episodes but are also at an increased risk of rapid worsening in their CKD stage and progression to ESRD following an episode of AKI. In addition, multiplicity in episodes of AKI reduces the time to reach ESRD. 8, 17, 24 Chawla et al. developed three multivariable models to help clinicians identify AKI survivors at increased risk of development of CKD and progression. The most clinically useful model was validated and is based on observed clinical events (i.e. RIFLE stage, need for dialysis, baseline eGFR, advanced age and serum albumin). 16 In addition to clinical parameters and biomarkers, noninvasive imaging techniques, including those that assess interstitial fibrosis and renal hypoxia, may provide additional information when identifying AKI survivors at risk of progression to CKD. Blood oxygen level-dependent magnetic resonance imaging (MRI) to measure renal hypoxia, 64 Cu-labelled collagen-specific peptides used in PET imaging and elastography techniques using MRI and fibrosis-specific contrast agents targeting collagen in MRI studies are some of the imaging techniques that could help us identify patients with progressive renal fibrosis following clinical recovery of AKI. 44 One of the non-invasive imaging techniques that looks promising for the future is the use of contrast-enhanced ultrasound (CEUSG). The gas-filled micro-bubbles that are non-nephrotoxic and restricted to intravascular compartment are superior for imaging intra-renal vasculature. Gigliotti et al. demonstrated reduced renal function deterioration and intra-renal accumulation of polymorphs, mononuclear phagocytes and chronic intra-renal collagen in mice following ischaemia-reperfusion injury with a 24-h prior exposure to ultrasound. It was secondary to post-injury immunomodulation by the splenic cholinergic antiinflammatory pathway. 70, 71 CEUSG has been shown to detect, stratify and monitor AKI and thus helps guide therapy. The ability to predict the progression to CKD following an episode of AKI using ultrasound-based tissue elasticity imaging and molecular ultrasound imaging, by attaching specific monoclonal antibody to the contrast agent shell surface via a high-affinity molecular bridge and non-invasive delivery of therapeutic agents to diseased or injured renal tissue using micro-bubbles are areas to look forward to in the future. 72 Timelines and criteria for defining recovery from an AKI episode have been variable across different studies. Recovery of renal function at hospital discharge, recovery at day 30 or day 90 and the likewise return of renal function to pre-AKI levels based on serum creatinine or eGFRs or dialysis independency at follow up have been variably used to define recovery. 73 Even for discerning long-term outcomes, follow up in patients with recovered AKI has been poorly defined. Studies have either used 1, 3 and/or 5-year follow ups, and the outcomes themselves are variably measured either in terms of mortality, doubling of serum creatinine or progression to CKD stage 4 or ESRD. 10, 14, 15, 17, 39, 69 Data on other long-term consequences such as cardiovascular outcomes are often not measured, adding to the difficulty in providing recommendations on clinical or biochemical parameters that need to be monitored after recovery from an episode of AKI. The importance of standardizing the definitions and having clinical timelines for recovery would help in triaging patients who require rigorous monitoring and help in providing individualized recommendations on duration and frequency of monitoring in AKI survivors. Based on the current available definitions and recommendations, all patients who had an episode of AKI should be assessed at least by day 7 and day 90 following the primary insult to differentiate AKI, AKD and CKD. 21, 74 This would provide opportunities for appropriate management, prognostication and interventions based on staging. Apart from evaluation for new-onset proteinuria and hypertension, one should also take a note of any worsening in pre-existing proteinuria and hypertension. Although current KDIGO guidelines recommend patients to be evaluated '3 months after AKI for resolution, new onset, or worsening of pre-existing CKD', 74 Ishani et al.
showed that the highest risk of progression to CKD was in the first 6 months after AKI from cardiac surgery, with a marked attenuation risk (but still statistically significant) at 1 year but an increased cardiovascular risk that persisted up to 5 years, 69 suggesting therefore that patients surviving an episode of AKI should be monitored for development of CKD for at least 1 year and for additional cardiovascular events for at least 5 years.
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TREATMENT OPTIONS TO REDUCE PROGRESSION TO CKD AND IMPROVE LONG-TERM OUTCOMES
Until now, most interventions in patients with AKI have been limited to improving short-term outcomes and survival of patients, with little focus on long-term consequences. As elucidated above, AKI and CKD share similar risk factors, and there are animal data that show similarities in the pathological processes that initiate CKD progression and those that occur following an episode of AKI. Therefore, in the absence of evidence pointing to the benefit of other riskmitigating strategies, targeting established pathways of progression in CKD are likely to be beneficial in AKI survivors to prevent, halt or retard the progression to CKD. 75 
General measures
In patients surviving an episode of AKI, the optimal recovery of renal functions can be facilitated by reversing prerenal causes, eliminating nephrotoxin exposure, correcting post-renal causes and specifically treating the inciting event that caused AKI. In patients developing AKI related to a glomerulonephritis, interstitial nephritis or vasculitis, early institution of specific treatment is likely to improve outcomes of the episode of AKI by successful repairing the renal parenchyma. One such therapy is the use of corticosteroids in patients with acute interstitial nephritis, known to reduce the severity and the duration of AKI. 76 Strategies to promote renal functional recovery, either at the time of insult (developmental phase) or during the extension phase of AKI, merit attention and investigation. One such promising molecule has been the SS-31 peptide. Szeto-Schiller (SS) peptides are novel mitochondrial protective drugs that selectively bind to cardiolipin on the inner mitochondrial membrane and improve mitochondrial respiration and ATP production. 77 The results from the extended study of Randomized Evaluation of Normal vs Augmented levels of RRT (POST-RENAL) cohort found no benefit in long-term mortality and ESRD progression based on the intensity of dialysis in the acute phase. 79 However, Bell et al., in collaboration with the Swedish Intensive Care Nephrology Group, concluded that CRRT compared with intermittent RRT had a bigger chance of renal recovery.
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There is also a need to increase awareness among general physicians about the long-term risk of an episode of AKI and the improved outcomes of early referral to and follow up by a nephrologist. Data from the Veterans Affairs database between January 2003 and December 2008 demonstrated a very low referral rate. Among 3929 hospitalized AKI survivors who had an eGFR less than 60 mL/min per 1.73 m 2 at day 30 of peak serum creatinine, only 8.5%
(95% CI = 7.6-9.4) were seen by a nephrologist at follow up. 81 The improved outcomes of an early nephrology referral were clearly demonstrated by a retrospective matched cohort study in Canada. Survivors of dialysis requiring AKI when seen by a nephrologist in the 90 days of discharge had lower all-cause mortality, 8.4 versus 10.6 per 100-patient years, HR 0.76 (95% CI = 0.62-0.93). 82 The implications of long-term outcomes following AKI and the high-risk group susceptible for such complications, including patients with advanced age, female gender, hospital-acquired AKI, preexisting CKD, heart disease, diabetes and other comorbidities, have been noted by the KDIGO group, which recommended the general management guidelines for patients with AKI. 74 This group of patients is more likely to benefit from measures taken to improve their general cardiovascular health. Patients with recurrent episodes of AKI should be evaluated to ascertain the cause of recurring events, and potential causes like cardio-renal syndrome need be addressed. More specifically, there is a need for more patient and community education on 'over-the-counter' medications that increase risk of AKI, especially non-steroidal antiinflammatory drugs (NSAIDs), and education on sick day medication lists like renin-angiotensin-aldosterone system (RAAS) blockers, NSAIDs, diuretics and metformin, which should be temporarily withheld when patients have reduced oral intake or predisposed to dehydration from a GI disturbance, thus preventing recurrent AKI in those at high risk.
Once patients have survived an episode of AKI, those patients with pre-existing CKD or those with partial recovery of renal functions would merit the institution of general measures, including control of hypertension and reduction of proteinuria by altering intra-glomerular haemodynamics by inhibition of the RAAS. In diabetics, use of sodiumglucose cotransporter 2 (SGLT2) inhibitor or dipeptidyl peptidase 4 (DPP4) inhibitors may provide additional renoprotection over and above that associated with glycaemic control. In the EMPA-REG OUTCOME trial, use of empagliflozin resulted in a relative risk reduction of 44 and 55% for doubling of serum creatinine and need for RRT, respectively, compared with the placebo arm. 83 In the SAVOR-TIMI 53 trial, use of saxagliptin (DPP4 inhibitor) improved the albumin-creatinine ratio over a median duration of 2.1 years, even in the normoalbuminuric range patients, without reducing eGFR. 84 Liraglutide, a glucagon-like peptide 1 analogue in type 2 diabetics, reduced new onset of persistent macroalbuminuria, compared with placebo (161 vs 215 patients; HR = 0.74; 95% CI = 0.60-0.91; P = 0.004) without an increase in adverse events. 85 Other potential interventions to halt or retard progression to CKD after AKI may include uric acid-lowering therapies that are currently being investigated by the CKD-FIX trial (ACTRN12611000791932) and PERL trials (NCT02017171) in patients with CKD, bicarbonate supplementation being investigated by BASE Study (NCT02521181), newer endothelin antagonists (previously, this class of drugs was shown to reduce proteinuria but was noted to cause higher CV events), 86 pentoxifylline (being investigated for renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease Study (NCT01377285), pyridoxamine (Pyridorinin Diabetic Nephropathy study (NCT02156843)) and paricalcitriol. 87 Potential pathways and specific targets for preventing progression of AKI to CKD in the future Considering the multifactorial aetiology, complex clinical interactions and recurring episodes in some, targeting the pathogenesis of AKI to CKD transition could offer more promise in improving long-term outcomes. Targeting the pericytes and abnormalities in the epithelial cell cycle using novel therapeutic strategies may address the development of fibrosis, maladaptive repair and microvascular rarefaction characteristic of progressive CKD after AKI and promote renal recovery.
Some of the measures successful in animal models have been the use of agents to block the pro-fibrotic signalling of G2/M-arrested cells (using JNK-pathway inhibition) or promote cells to transit through G2/M phase to complete mitosis by using agents such as histone deacetylase inhibitors or p53 inhibition. Agents promoting the apoptosis or pharmacological depletion of these arrested cells have also been successful in rodents; however, for use in humans, further investigation into the safety of these drugs will be needed considering their tumorigenic potential. Experimental models have demonstrated the utility of treatment with angiogenic factors such as vascular endothelial growth factor-121 in the immediate post-insult period by reducing vascular dropout and endothelial damage. 75 The hedgehog (Hh) pathway transcriptional effector GLI2 expressed in myofibroblast progenitors drives myofibroblast cell cycle progression. In animal trials, the GLI inhibitor GANT61 and darinaparsin reduced fibrosis through the reduction of GLI2 protein levels and subsequent cell cycle arrest in myofibroblasts. 88 Even though the pharmacological agents to improve long-term outcomes following AKI look promising, caution is needed when considering the potential for some of these agents to be carcinogenic on long-term use. One also needs to know the therapeutic utility of these agents to oppose the maladaptive process when used in the later period, following the primary insult.
CONCLUSIONS
A single episode of AKI, regardless of its severity or aetiology, can have far-reaching renal and systemic consequences. It is necessary to emphasize not only the importance of early detection and prompt management of AKI but also the need for long-term follow up of AKI patients. Use of biomarkers and clinical scoring scales in the acute phase to predict long-term outcomes is an area of significant interest among researchers. The ASSESS-AKI study and ARID study are ongoing prospective studies that could determine the natural history of AKI and long-term renal and non-renal outcomes in general hospitalized population, including the less severe AKI and pre-renal AKI cases. Prevention of AKI in the community by eliminating nephrotoxic drug exposure in patients at risk and education on sick day medications list on drugs that should be avoided when patients are unwell at home are low-cost strategies that are worth implementing. Further progress on drugs that could prevent AKI even after the insult in hospitalized patients in high-risk settings include new and emerging strategies that would be worth exploring. Early recognition and appropriate management of patients with incomplete kidney recovery with current strategies may delay the progression of CKD to ESRD and continues to be an open field for ongoing research. Future directions would include the use of traditional or novel biomarkers and non-invasive imaging techniques indicative of interstitial fibrosis at 3 month follow up after an AKI episode to identify subclinical CKD and follow up patients to recognize its relevance to prediction in longterm outcomes and development of therapeutic agents to specifically halt or reduce the maladaptive process after AKI even when used in the delayed phase following an insult. In addition, there needs to be an increasing awareness among primary care physicians on the long-term consequences in AKI survivors and the need for specialist follow-up care.
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